ACADIA PHARMACEUTICALS INC. State and Local Income Tax Expense (Benefit), Continuing Operations
ACADIA PHARMACEUTICALS INC. (ACAD) reported State and Local Income Tax Expense (Benefit), Continuing Operations of $31.60 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Expense Statement › Income Tax
us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations · last filed 2025-02-27
- ACADIA PHARMACEUTICALS INC. state and local income tax expense (benefit), continuing operations for fiscal 2024 was $31.60M, a 206.80% increase from fiscal 2023.
- ACADIA PHARMACEUTICALS INC. state and local income tax expense (benefit), continuing operations for fiscal 2023 was $10.30M, a 312.00% increase from fiscal 2022.
- ACADIA PHARMACEUTICALS INC. state and local income tax expense (benefit), continuing operations for fiscal 2022 was $2.50M, a 525.00% increase from fiscal 2021.
- ACADIA PHARMACEUTICALS INC. state and local income tax expense (benefit), continuing operations for fiscal 2021 was $400.00K, a 0.00% change from fiscal 2020.
| Period end | State and Local Income Tax Expense (Benefit), Continuing Operations 12 month | State and Local Income Tax Expense (Benefit), Continuing Operations 12 month as first filed |
|---|---|---|
| 2024-12-31 | $31.60M 10-K · filed 2025-02-27 | |
| 2023-12-31 | $10.30M 10-K · filed 2025-02-27 | |
| 2022-12-31 | $2.50M 10-K · filed 2025-02-27 | |
| 2021-12-31 | $400.00K 10-K · filed 2023-02-28 | |
| 2020-12-31 | $400.00K 10-K · filed 2023-02-28 | |
| 2019-12-31 | $900.00K 10-K · filed 2022-03-01 | |
| 2018-12-31 | $1.30M 10-K · filed 2021-02-25 | |
| 2017-12-31 | $1.10M 10-K · filed 2020-02-27 | |
| 2016-12-31 | $1.30M 10-K · filed 2019-02-27 | |
| 2015-12-31 | $300.00K 10-K · filed 2018-02-27 | $330.00K 10-K · filed 2016-02-29 |
| 2014-12-31 | $0.00 10-K · filed 2017-02-28 | |
| 2013-12-31 | $0.00 10-K · filed 2016-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |